What is the Phosphatidylethanol (PEth) homologues test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Phosphatidylethanol (PEth) Homologues Test

Phosphatidylethanol (PEth) homologues test is a highly sensitive and specific biomarker test that detects direct products of ethanol metabolism in blood, capable of detecting a single drinking episode for up to 12 days and chronic heavy alcohol use for up to 6 weeks. 1

What is PEth?

  • PEth represents a group of glycerophospholipid homologues formed specifically when ethanol binds to phospholipids through the action of phospholipase D 2
  • PEth is a direct biomarker of alcohol consumption with theoretically 100% diagnostic specificity since its formation requires the presence of ethanol 2
  • PEth consists of multiple homologues that differ in their fatty acid chain length and degree of unsaturation 3, 4
  • The most commonly measured homologue is PEth 16:0/18:1, which is the major homologue in blood samples from alcoholics 3
  • Other prevalent homologues include PEth 16:0/18:2,18:0/18:2, and 18:0/18:1 3, 5

Clinical Utility

  • PEth testing is now commonly used in the US and Europe to monitor alcohol use in liver transplant centers 1
  • PEth levels directly correlate with the amount of alcohol consumed, making it a semi-quantitative measure of alcohol intake 1
  • PEth has a half-life of approximately 4 days in blood 2
  • PEth is more sensitive than traditional alcohol markers such as CDT (carbohydrate-deficient transferrin), GGT (gamma-glutamyl transferase), and MCV (mean corpuscular volume) 2

Interpretation of Results

  • In US commercial labs, 20 ng/ml is the minimum reporting threshold for a positive test 1
  • A PEth range of 20–200 ng/ml may indicate alcohol use consistent with MetALD (Metabolic dysfunction and Alcohol-related Liver Disease), which is defined as 20–60 g/day or 140–420 g/week 1
  • PEth levels >200 ng/ml (typically >500 ng/ml) are consistent with drinking above the MetALD range (>50 g/day in women and >60 g/day in men) 1
  • In Sweden, a PEth level above 0.30 μmol/L (~210 μg/L) is considered a strong indicator of harmful drinking 6

Advantages Over Other Alcohol Biomarkers

  • PEth has higher specificity compared to indirect markers like GGT, AST, ALT, and MCV, which can be altered by other conditions such as drug ingestion, liver disease, or muscle disease 1
  • Unlike ethanol testing in blood, breath, or urine, PEth has a much longer detection window 1
  • PEth is not affected by the presence of compensated or decompensated cirrhosis, unlike some other markers 1
  • PEth can detect a single drinking episode for up to 12 days and chronic heavy use for up to 6 weeks 1

Limitations and Considerations

  • PEth only correlates with recent alcohol use and does not account for historical alcohol use 1
  • PEth testing should be used as an adjunct to alcohol history taking, standardized questionnaires, and collateral information 1
  • The applicability of PEth testing may be limited by its cost 1
  • Due to interindividual variations in test response and elimination half-life, it is not possible to indicate the exact amount or time of alcohol intake 6

Technical Aspects

  • Modern PEth analysis typically uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) for high sensitivity and specificity 4, 5
  • Up to 48 different homologues of PEth have been identified in blood using LC-ESI-MS/MS 4
  • Dried blood spots can be used for PEth analysis, allowing for easier sample collection and storage 5

PEth homologues testing represents a significant advancement in alcohol biomarker testing, providing clinicians with a reliable tool to detect and monitor alcohol consumption in various clinical settings, particularly in liver disease management and transplantation evaluation 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.